OncoNano Medicine to Present at the American Association for Cancer Research (AACR) Annual Meeting 2023
2023-03-15
临床2期AACR会议免疫疗法
SOUTHLAKE, Texas--(BUSINESS WIRE)-- OncoNano Medicine, Inc. today announced three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023 at the Orange County Convention Center, Orlando, Florida.
Presentation Overview:
TITLE:
Improved tolerability and tumor specific delivery of a therapeutic bispecific T cell engager using a pH-sensitive nanoparticle platform
PRESENTER:
Qingtai Su, Ph.D.
DATE:
April 16, 2023
TIME:
1:30 – 5:00 PM ET
SECTION and PRESENTATION NUMBER:
Poster Section 30, No. 815
TITLE:
Encapsulation of IL-12 with an ultra pH-sensitive nanoparticle platform improves tolerability and promotes antitumor response in mice
PRESENTER:
Tian Zhao, Ph.D.
DATE:
April 16, 2023
TIME:
1:30 – 5:00 PM ET
SECTION and PRESENTATION NUMBER:
Poster Section 34, No. LB001
TITLE:
ONM-501, a dual-activating polyvalent STING agonistpolyvalent STING agonist, enhances tumor retention and demonstrates favorable preclinical safety pro >
PRESENTER:
Zirong Chen, Ph.D.
DATE:
April 18, 2023
TIME:
1:30 – 5:00 PM ET
SECTION and PRESENTATION NUMBER:
Poster Section 34, No. LB245
About OncoNano Medicine
OncoNano Medicine is developing a new class of products that utilize principles of molecular cooperativity in their design to exploit pH as a biomarker to diagnose and treat cancer with high specificity. Our product candidates and interventions are designed to help patients across the continuum of cancer care and include solid tumor therapeutics, agents for real-time image guided surgery and a platform of immune-oncology therapeutics that activate and guide the body’s immune system to target cancer.
OncoNano’s lead development candidate is pegsitacianine, a novel fluorescent nanoprobe using the ONBOARD platform, that is currently under study in Phase 2 clinical trials as a real-time surgical imaging agent for use in multiple cancer surgeries. ONM-501, OncoNano’s second development program, is a next generation STING (STimulator of INterferon Genes) agonistSTING (STimulator of INterferon Genes) agonist that is advancing towards a first in human trial in the first half of 2023. Pegsitacianine and ONM-501 have been supported by grants received from the Cancer Prevention Research Institute of Texas. Learn more at .
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。